FDA clears Denali drug in ‘clear step’ for rare disease biotechs
Source: BioPharma Dive - Latest News
The approval of Denali’s Hunter syndrome treatment, Avlayah, comes after a series of drug rejections and delays that had led to criticism of the FDA’s stance on rare disease therapies.